{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:05Z","timestamp":1792785845015,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["P500PM_202961"],"award-info":[{"award-number":["P500PM_202961"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SICPA Foundation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA015704-47"],"award-info":[{"award-number":["P30 CA015704-47"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The epidemiology of cytomegalovirus (CMV) after chimeric antigen receptor\u2013modified T-cell immunotherapy (CARTx) is poorly understood owing to a lack of routine surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively enrolled 72 adult CMV-seropositive CD19-, CD20-, or BCMA-targeted CARTx recipients and tested plasma samples for CMV before and weekly up to 12 weeks after CARTx. We assessed CMV-specific cell-mediated immunity (CMV-CMI) before and 2 and 4 weeks after CARTx, using an interferon \u03b3 release assay to quantify T-cell responses to IE-1 and pp65. We tested pre-CARTx samples to calculate a risk score for cytopenias and infection (CAR-HEMATOTOX). We used Cox regression to evaluate CMV risk factors and evaluated the predictive performance of CMV-CMI for CMV reactivation in receiver operator characteristic curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CMV was detected in 1 patient (1.4%) before and in 18 (25%) after CARTx, for a cumulative incidence of 27% (95% confidence interval, 16.8\u201338.2). The median CMV viral load (interquartile range) was 127 (interquartile range, 61\u2013276) IU\/mL, with no end-organ disease observed; 5 patients received preemptive therapy based on clinical results. CMV-CMI values reached a nadir 2 weeks after infusion and recovered to baseline levels by week 4. In adjusted models, BCMA-CARTx (vs CD19\/CD20) and corticosteroid use for &amp;gt;3 days were significantly associated with CMV reactivation, and possible associations were detected for lower week 2 CMV-CMI and more prior antitumor regimens. The cumulative incidence of CMV reactivation almost doubled when stratified by BCMA-CARTx target and use of corticosteroids for &amp;gt;3 days (46% and 49%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CMV testing could be considered between 2 and 6 weeks in high-risk CARTx recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad708","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T10:19:43Z","timestamp":1700129983000},"page":"1022-1032","source":"Crossref","is-referenced-by-count":60,"title":["Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-3073","authenticated-orcid":false,"given":"Eleftheria","family":"Kampouri","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S","family":"Ibrahimi","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Wong","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B","family":"Hecht","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep K","family":"Sekhon","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alythia","family":"Vo","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L","family":"Stevens-Ayers","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J","family":"Green","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Maloney","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailyn","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R","family":"Jerome","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Hill","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"2024041017092017700_ciad708-B1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"2024041017092017700_ciad708-B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2024041017092017700_ciad708-B6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2024041017092017700_ciad708-B7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"2024041017092017700_ciad708-B10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2024041017092017700_ciad708-B11","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"2024041017092017700_ciad708-B12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024041017092017700_ciad708-B13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2024041017092017700_ciad708-B14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024041017092017700_ciad708-B15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"2024041017092017700_ciad708-B16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"2024041017092017700_ciad708-B17","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211025503","article-title":"Incidence and risk factors associated with infection after chimeric antigen receptor T cell therapy for relapsed\/refractory B-cell malignancies","volume":"30","author":"Zhu","year":"2021","journal-title":"Cell Transplant"},{"key":"2024041017092017700_ciad708-B18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2021","journal-title":"Eur J Haematol"},{"key":"2024041017092017700_ciad708-B19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024041017092017700_ciad708-B20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024041017092017700_ciad708-B21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2024041017092017700_ciad708-B22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"2024041017092017700_ciad708-B23","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024041017092017700_ciad708-B24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"key":"2024041017092017700_ciad708-B25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cmi.2023.05.010","article-title":"Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?","volume":"29","author":"Solano de la Asunci\u00f3n","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024041017092017700_ciad708-B26","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2024041017092017700_ciad708-B27","first-page":"2365","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024041017092017700_ciad708-B28","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"2024041017092017700_ciad708-B29","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024041017092017700_ciad708-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024041017092017700_ciad708-B31","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024041017092017700_ciad708-B32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"2024041017092017700_ciad708-B33","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"2024041017092017700_ciad708-B34","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"key":"2024041017092017700_ciad708-B35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024041017092017700_ciad708-B36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CJI.0000000000000388","article-title":"CMV and HSV pneumonia after immunosuppressive agents for treatment of cytokine release syndrome due to chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy","volume":"44","author":"Heldman","year":"2021","journal-title":"J Immunother"},{"key":"2024041017092017700_ciad708-B37","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"key":"2024041017092017700_ciad708-B38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-\u03b3-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad708\/54723438\/ciad708.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/1022\/57209263\/ciad708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/4\/1022\/57209263\/ciad708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T14:13:12Z","timestamp":1712758392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/4\/1022\/7425426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,17]]},"published-print":{"date-parts":[[2024,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad708","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,15]]},"published":{"date-parts":[[2023,11,17]]}}}